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ABSTRACT 
 
Layer-by-layer (LbL) capsules, known for their versatility and smart response to 
environmental stimuli, have attracted great interest in drug delivery applications. 
However, achieving a desired drug delivery system with sustained and tunable drug 
release in response to temperature is still challenging.  Here, a thermo-responsive drug 
delivery system of solid dexamethasone nanoparticles (DXM NPs) encapsulated in a 
model LbL assembly of strong polyelectrolytes poly (diallyldimethylammonium 
chloride)/poly (styrene sulfonate) (PDAC/PSS) was constructed. 
DXM NPs at an average size of 201  96 nm were fabricated. ζ-potential 
measurements, X-ray photoelectron spectroscopy, and transmission electron microscopy 
confirmed the successful adsorption of each layer. The influence of various parameters 
on drug release, such as number of layers, ionic strength of the adsorption solution, 
temperature and outer-most layer, has been investigated. Results have shown a 
controlled DXM release from LbL nanoshells by tuning number of layers and ionic 
strength of the adsorption solution. The DXM release from linearly growing LbL of 
PDAC/PSS (assembled without NaCl), which do not exhibit a glass transition, 
experienced a more temperature response than those from exponentially growing LbL of 
PDAC/PSS (assembled at 0.5 M NaCl), which exhibit a glass transition. Such a 
difference was attributed to be related with the free volume cavities within the 
assemblies. By tailoring the properties of those cavities, an ideal thermo-responsive drug 
delivery system may be obtained. This thermo-responsive NP-based drug delivery 
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system with tunable permeability may possibly realize an “on” or “off” drug release 
mechanism in response to temperature, thus providing an alternative approach to 
delivery therapeutics with reduced toxic effects. 
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1. INTRODUCTION 
 
1.1 Motivation and Hypothesis 
Cancer, known as a broad group of diseases involving unregulated cell growth, is 
the leading cause of death worldwide. The transformation of a normal cell into a cancer 
cell is identified with the alteration of genes regulating cell growth and differentiation.1 
The search for the origin and treatment of cancer remains a grand challenge.2  
To date, effective cancer treatments include chemotherapy, surgery, radiation, 
and immunotherapy. Recently, combination therapy under remote physical controls has 
received great attention as a new theranostic approach to decrease systemic toxicity, and 
avoid overdosing. External stimuli, including light, magnetic field, electric field, and 
heat, have been used to trigger, control, and enhance localized cancer therapies. 2 
Because heat can be utilized to directly destroy cancer cells, the delivery of anti-cancer 
drug triggered by heat is of special interest for combined cancer treatment. 
Layer-by-layer (LbL) capsules, which are nanoscale shells built up through the 
alternating adsorption of oppositely charged polyelectrolytes on a spherical substrate via 
electrostatic interactions, have attracted great interest for use as multifunctional 
therapeutic delivery vehicles.3,4, 5,6 The highly versatile LbL assembly technique allows 
one to engineer the size, shape, permeability, and surface functionality of capsules by 
simply selecting layer species and assembly conditions, such as ionic strength,7,8 pH,9,10 
and temperature.11,12,13 However, a “smart” delivery system, where permeability changes 
in response to environmental stimuli, still wait to be explored. 
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Very recently a class of layer-by-layer (LbL) assemblies has been found to 
exhibit a glass transition at slightly above the body’s physiological temperature. For 
example, Vidyasagar et al.14 in our group found a step increase in viscoelasticity for 
hydrated exponentially growing LbL assemblies of strong polyelectrolytes poly 
(diallyldimethylammonium chloride)/poly (styrene sulfonate) (PDAC/PSS) at 49-56 oC, 
coinciding with films’ glass transition temperature (Tg), Figure 1-1. No distinct transition 
was observed for linearly growing assemblies at this temperature window. The increase 
in viscoelasticity was attributed to the breaking of ion pairs and subsequent chain 
relaxation, reflecting an increase in polymer chain mobility. As suggested by 
Johansson, 15  solute diffusion increases as polymer chains become more flexible, 
providing evidence that polymer chain mobility is an important governing factor. Ion 
transport through polymers such as poly (ethylene oxide) typically jumps at temperatures 
around the Tg.
16  Thus we hypothesize that the distinct glass transition observed in 
exponentially growing PDAC/PSS LbL assemblies may cause an enhancement in drug 
permeability, which motivated us to develop a thermo-responsive drug delivery system 
by assembling PDAC/PSS onto solid drug nanoparticles to form a core-shell structure. If 
such a hypothesis is true, one might expect a greater response to temperature for the 
release of drug from exponentially growing PDAC/PSS nanoshells as compared to drug 
release from linearly growing PDAC/PSS nanoshells.  
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Figure 1-1. Chemical structures of PDAC and PSS; reproduced from 17,18. 
 
 
 
Dexamethasone, a synthetic gluococorticoid that suppresses inflammation and 
autoimmune conditions, is given to cancer patients undergoing chemotherapy to reduce 
nausea and other side effects of cancer treatment, 19, 20 Figure 1-2. Dexamethasone is 
partly water-soluble; the solubility in PBS is about 140 µg/ml. 21  However, 
dexamethasone can cause serious systemic side effects including hypertension, 
psychiatric disturbances and diabetes mellitus. To avoid these side effects, a controlled 
and continuous delivery of dexamethasone is desired.  
 
 
 
 
 
 
Figure 1-2. Chemical structure of dexamethasone; reproduced from 22. 
Poly (styrene sulfonate) (PSS) Poly (diallyldimethylammonium chloride) 
(PDAC) 
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In this present study, a thermo-responsive drug delivery system of solid 
dexamethasone nanoparticles (DXM NPs) encapsulated in a model layer-by-layer (LbL) 
assembly of strong polyelectrolytes poly (diallyldimethylammonium chloride)/poly 
(styrene sulfonate) (PDAC/PSS) will be constructed. Specifically, the effect of 
temperature on DXM release will be investigated.  
 
1.2 Specific Aims  
1.2.1 Fabrication and LbL encapsulation of dexamethasone based core-shell structured 
nanoparticles 
         This thermo-responsive drug delivery system consists of a dexamethasone based 
core encapsulated by LbL assemblies of strong polyelectrolytes PDAC/PSS, Figure 1-3. 
The solid dexamethasone drug nanoparticles will be fabricated by a modified emulsion 
solvent evaporation technique and then encapsulated into PDAC/PSS synthetic polymers 
through a layer-by-layer assembly technique.  
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Figure 1-3. PDAC/PSS layer pairs assembled on drug nanoparticles 
 
 
1.2.2 In vitro dexamethasone release studies 
The dexamethasone release from PDAC/PSS LbL shells will be determined by 
measuring drug concentration versus time. It was observed18 that there was a glass 
transition at 49-56 oC for PDAC/PSS LbL assembled at 0.5 M NaCl, while no glass 
transition was observed for those assembled without NaCl. Thus the PDAC and PSS 
LbL shells will be assembled at 0.5 M NaCl and no NaCl respectively and release 
experiments will be conducted at 37 oC and 60 oC. The effect of varying (i) number of 
layers, (ii) ionic strength of the adsorption solutions, (iii) temperature, and (iv) outer-
most layer on dexamethasone release will be examined.  
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2. LITERATURE REVIEW 
 
2.1 Introduction 
This present chapter introduces the development of nanoparticle-based drug 
delivery system for cancer treatment, applications of layer-by-layer capsules in drug 
delivery, factors affecting the permeability of LbL assemblies, and existing examples of 
thermo-responsive layer-by-layer capsules. This chapter gives an insight into the 
interplay of physiochemical parameters and LbL properties, providing a guide in the 
design of thermo-responsive drug delivery vehicles.  
 
2.2 Nanoparticle-Based Drug Delivery Systems 
Drug delivery systems are designed to improve the therapeutic properties of 
conventional (“free”) drugs, where free drugs are primarily encapsulated within, or 
attached to, lipids or polymers. Examples of problems associated with free drugs include 
poor drug solubility, loss of activity in vivo, unfavorable pharmacokinetics, and poor 
biodistribution. 23  Efficient drug delivery systems allows for precisely controlled 
pharmacokinetics and preferentially localized sites of delivery to reduce systemic side 
effects and dosages required.24,25  
With the emergence of nanotechnology, nanoparticle-based therapeutics has 
significant potential to revolutionize medical treatment with more potent and less toxic 
delivery systems.26, 27 With substantial efforts devoted into this field, a few nanoparticle-
based formulations, such as protein-based nanoparticles (NPs) (Abraxane®, Celgene 
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Corporation), lipid-based NPs (Inflexal® V, Crucell), and polymer-based NPs 
(ELIGARD®, Sanofi), have been approved by the FDA for clinical use. One important 
advantage of NPs as drug delivery systems is targeting because their small size can 
efficiently penetrate across biological barriers.28 Intravenously administered therapeutics 
circulates in the bloodstream and interacts with the reticuloendothelial system (RES), a 
part of the immune system to clear foreign entities, prior to arriving at the target site. 
The efficiency of NPs to target at the site of diseases is dependent on a number of factors 
including size, shape, and surface chemistry.29 For tumor targeting, particles less than 
250 nm are preferred because they are more likely to cross the extravasation (leaky 
endothelium of tumor). The shape of particles is known to affect the flowing directions 
in which particles flow through a vessel. Because particles interact with various 
components of the blood while flowing through the vessel, surface functionality of 
particles is an effective strategy to prevent particles being cleared by the RES and hence 
prolong the circulation time. For example, particles functionalized with hydrophilic 
polymers such as polyethylene glycol (PEG) have been shown to prolong the circulation 
time by minimizing their interactions with the RES. 29 
Numerous polymer-based delivery systems have been developed to encapsulate 
therapeutics. As shown in Figure 2-1, the drug is encapsulated into a polymer membrane 
in a reservoir system; the drug is evenly distributed through a polymer system in a 
matrix system. By selecting appropriate polymers according to the goal of the drug 
delivery system, various properties such as formulation, particle size, permeability, and 
sustained-release properties may be tuned. Despite existing strategies render solutions to 
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achieve the goal of reducing toxic effects, achieving the desired NP-based drug delivery 
system with such versatility is still challenging. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-1. Examples of polymer-based delivery system. Small dots represent 
drug, and arrows show the direction in which drug is released. a) reservoir 
system, b) matrix system (reproduced from reference 25). 
 
 
2.3 Layer-by-Layer (LbL) Capsules for Drug Delivery 
LbL assembly, pioneered by Decher, is a technique for the construction of 
nanoscale films by alternate adsorption of polyelectrolytes from aqueous solution.30 
Interactions between polyelectrolytes, including electrostatic, hydrogen bonding, and 
Van der Waals, have been considered to drive the formation of these nanoscale films, 
but entropy is the major driving force. Various substrates, such as glass slides, charged 
particles, carbon nanotubes, and porous membranes, have been used as supports for 
building these LbL assemblies. 
Recently, layer-by-layer (LbL) particles, which are nanoscale shells built up 
through the alternate adsorption of oppositely charged polyelectrolytes on a spherical 
a) b) 
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substrate, have attracted great interest for use as multifunctional therapeutic delivery 
vehicles.3,4,5,6 These coated LbL particles are considered core-shell particles. By removal 
of the sacrificial particle core, hollow LbL capsules are formed. Therapeutics including 
small molecule drugs, peptides, proteins, and growth factors can be loaded into capsules 
and released at a desired rate. The highly versatile LbL assembly technique allows one to 
engineer the size, shape, permeability, and surface functionality of capsules by simply 
selecting layer species and assembly conditions, such as ionic strength,7,8 pH,9,10 and 
temperature.11,12,13 However, a “smart” delivery system, where the permeability of 
microcapsules or nanoshells changes in response to environmental stimuli, still waits to 
be explored. External stimuli including salt,31 pH, heat,32,33 and light34 can induce the 
permeability changes, Figure 2-2. For example, Möhwald and co-workers prepared 
hollow capsules of poly (allylamine) (PAH)/PSS. The permeability of the capsule was 
found to be reversibly switched between an open and a closed state for PAH (70000 
g/mol) by changing the adsorption salt concentration from 5 to 20 mM. Tsukruk et al. 
reported the pH-responsive permeability of hydrogen bonded hollow microcapsules of 
tannic acid assembled with a range of neutral polymers, poly(N-vinylpyrrolidone) 
(PVPON), poly(N-vinylcaprolactam) (PVCL) or poly(N-isopropylacrylamide) 
(PNIPAM). 35  These stimuli-responsive phenomena reveal the complex nature of 
polyelectrolytes and highlight the interplay of parameters which can affect the 
permeability of microcapsules or nanoshells.36 
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Figure 2-2. Schematic illustration of stimuli for microcapsule loading and release 
(Reproduced from 36). 
 
 
2.4 Factors Affecting the Permeability of LbL Assemblies 
For drug release, the permeability of capsules is particularly important in order to 
achieve the proper release profile over a given period of time. Studies on the 
permeability of LbL assemblies have been reviewed by Mansouri and co-workers.37 
Physicochemical parameters including ionic strength, layer number, and pH have been 
reported to affect the permeability of LbL assemblies. To investigate the permeability of 
LbL microcapsules or nanoshells, several methods are indicated in the literature. One 
method is to add a fluorescent probe solution to the capsules and to monitor the 
permeation of the probe into capsules by means of confocal laser scanning imaging 
(CLSM).31 A second method is to encapsulate a crystalline material within the LbL 
shells and measure the release of core material into the bulk solution.38 A more recent 
approach is by applying a molecular beacon (MB) technique, where MB-functionalized 
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particles are encapsulated within LbL shells and then incubated with DNA target 
sequences of different lengths. Permeation of the DNA target causes the hybridization of 
DNA targets with the complimentary loop regions of the MBs, resulting in an increase in 
MB fluorescence.39   
It is well known that the diffusion of solute through the LbL film is likely to take 
place through water-filled cavities existing in LbL films.40, 41 Any factor which can alter 
the size of these spaces, including polymer chain mobility, the size of the solute in 
relation to the size of the cavities, and the existence of charged groups on the polymer 
which may bind the solute molecule, will cause a variation in the diffusivity of a solute.42 
Because local defects, or free volume cavities existing in LbL films are crucial for 
controlled release applications, attempts to probe the nanoscale porosity of LbL films 
have been reported by several groups. Chavez and Schӧnhoff estimated the porosity of 
PAH/PSS LbL shells formed on colloidal particles using NMR cryoporometry, and 
found that the pore size was ~1 nm.43 Quinn et al. made use of positron annihilation 
spectroscopy (PAS) technique to measure the Ångstrӧm-scale free volume, and 
investigated the effect on the free element volume size and concentration elements in 
LbL of varying film assembly conditions.44 They found that depending on the number of 
layer pairs and the assembly conditions selected, the diameters of free volume cavities 
can be tuned from 0.4 to 0.6 nm, and the total free volume concentrations varies from 
1.1×1020 to 4.3×1020 cm-3.44 Other investigation by Köhler et al.,45 using a permeation 
approach by encapsulating fluorescent dextran with different molecular weights and 
quantifying the entrapped amount after release, estimated an apparent mesh size of 13 
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nm for PSS-terminated PDAC/PSS LbL microcapsules. This value was attributed to the 
large defects within the PDAC/PSS LbL.  
 
2.5 Thermo-Responsive LbL Capsules 
Thermo-responsive LbL assemblies were introduced via several approaches over 
the past decade. A well-known approach is to introduce thermo-responsive polymers 
undergoing coil-globular phase transitions into LbL assemblies. When temperature is 
raised above a low critical solution temperature (LCST), thermo-responsive polymers 
transition from a collapsed dehydrated state to a swollen state causes an 
increase/decrease in the permeability depending on LbL assembly conditions. For 
example, Quinn and Caruso 46  assembled hydrogen bonded LbL films of poly (N-
isopropylacrylamide) (PNIPAAm)/poly (acrylic acid) (PAA) and found a temperature-
dependent dye loading and release behavior. Such a behavior was attributed to depend on 
molecular interactions between the probe molecule and PNIPAAm. The addition of a 
hydrophobic moiety within the assemblies could significantly decrease dye release rate 
as well as enhance the thermo-responsive performance of films. Sukhishvili et al. 
47 incorporated triblock copolymers poly(N,N-dimethylaminoethyl methacrylate)-b-
poly(propylene oxide)-b-poly(N,N-dimethylaminoethyl methacrylate) (PD-PPO-PD) 
into LbL assemblies.  Because the dehydration temperature of the central PPO block was 
strongly dependent on pH, a dual pH and temperature-responsive reversible swelling and 
deswelling properties was observed. Wang et al.48 assembled PNIPAAm/alginate acid on 
MnCO3 cores and obtained microcapsules after removal of the templates.  Thermo-
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sensitivity due to the conformation change of PNIPAAm, and pH-sensitivity due to the 
cross linking of Mn2+ were observed in such microcapsules.  
It has been considered that factors, such as the presence of excess charge or the 
intermolecular association of polymer units, affect polymers temperature 
responsiveness.49 The presence of extra charge within LbL films was shown to suppress 
the temperature-responsiveness of films via enhanced film swelling. 50  An increased 
complexation of hydrogen bonded multilayers of poly(methacrylic acid) 
(PMAA)/poly(N-vinylcaprolactam) (PVCL) and PMAA/poly(vinyl methylether) 
(PVME) with poly(carboxylic acids) was shown to suppress thermo-responsive 
properties, indicating that the strength of intermolecular interaction plays an important 
role in polymers temperature responsiveness.33 
Glass transition corresponding to a change in mobility/viscoelasticity is also 
known to affect films permeability. Lin et al. 51  discovered that the water vapor 
permeability to poly(ethylene oxide glycol)/polybutyleneadipate multiple-polyol system 
of polyurethane films increases dramatically at temperatures near the films’ glass 
transition temperature(Tg). Other than these advances, very little is known about the 
permeability of LbL films in response to the glass transition.  
As shown by Vidyasagar et al.14 in our group, a glass transition was observed for 
for hydrated exponentially growing LbL assemblies of strong polyelectrolytes 
PDAC/PSS. In this present thesis, PDAC/PSS LbL assemblies will be coated onto drug 
nanoparticles. Several remarkable works on the thermal behavior of PDAC/PSS LbL 
microcapsules have been done. Mueller et al.52 reported that PDAC/PSS LbL capsules 
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experienced a melting process from glassy to viscoelastic state at 35-40 oC, where the 
Young’s modulus decreases significantly as measured by means of Atomic Force 
Microscopy (AFM). This was attributed to the breakage of ionic bonds, allowing the 
rearrangement of oppositely charged polyelectrolytes to occur. Köhler et al.53 observed 
an “odd-even” effect on PDAC/PSS LbL capsules, where PSS-terminated capsules 
shrank at 35-40 oC upon heating and PDAC-terminated ones swelled, as determined by 
CLSM and scanning electron microscopy (SEM). Ghostine and Schlenoff54 reported that 
the diffusion coefficient of ferricyanide probing ions through PSS–terminated 
PDAC/PSS LbL films increased strongly upon heating (14-50 oC); however, no clear 
phase transition was observed. 
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3. MATERIALS AND METHODS 
 
3.1 Introduction 
This chapter presents the materials and methods used in this study. 
Dexamethasone nanoparticles (DXM NPs) were fabricated by a two organic solvent 
evaporation technique. LbL assemblies were coated onto DXM NPs from different 
assembly conditions. ζ -potential measurements, X-ray photoelectron spectroscopy 
(XPS), and transmission electron microscopy (TEM) were used to confirm the success of 
layer adsorption. In vitro release studies of dexamethasone from PDAC/PSS LbL NPs 
were carried out at 37 oC and 60 oC. The concentration of released dexamethasone was 
assayed by high performance liquid chromatography (HPLC). 
 
3.2 Materials 
Poly (diallyldimethylammonium chloride) (PDAC, Mw~350 000 g/mol) and 
poly (styrene sulfonate sodium salt), (PSS, Mw~500 000 g/mol) were purchased from 
Sigma Chemicals and Scientific Polymer Products respectively. USP grade 
dexamethasone was obtained from Sigma Chemicals. Acetone and n-Heptane were 
purchased from Sigma Chemicals, USA, and Acros Organics respectively. HPLC grade 
acetonitrile and water were purchased from Avantor Materials. Ultrapure water used for 
all experiments was obtained from a Pall Corporation CascadaTM LS-water purification 
system with a specific resistance of 18.2 MΩ/cm. Phosphate-buffered saline solution 
(PBS, pH=7.4) consisted of 1.1 mM potassium phosphate monobasic, 3 mM sodium 
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phosphate dibasic heptahydrate, and 0.15 M sodium chloride. VWR syringe filters of 
size 0.2 μm were purchased from VWR and BD syringes were purchased from BD. A 
Fisher Scientific Marathon 16KM Centrifuge and an Eppendorf Centrifuge 5804 were 
used for the centrifugation procedures. 
 
3.3 Preparation of DXM NPs  
DXM NPs were prepared by a modified solvent evaporation technique described 
elsewhere.55, 56, 57 In this technique, immiscible liquids form droplets of  drug, which are 
hardened by solvent evaporation to form micro or nano particles.58 Here, a solution of 
dexamethasone in acetone (0.5%w/v) was mixed into n-Heptane with a v/v ratio of 2 to 
1 at 50 oC for 30 min. To ensure that n-Heptane was completely removed, DXM NPs 
were resuspended in PBS and constantly stirred overnight at room temperature. All 
nanoparticles were stored in a refrigerator until future use. The encapsulation efficiency 
(E.E.) of DXM NPs was calculated as the mass ratio of DXM mass encapsulated and the 
initial DXM mass. To measure the DXM mass encapsulated, 10 μl of DXM NPs from 
the stock solution were dissolved in 1 mL acetonitrile and its concentration was 
determined by HPLC analysis described later.  
DXM NPs E.E. % = 
Mass of DXM encapsulated in NPs
Mass of DXM initially fed
 ×100%                  3-1 
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3.4 Layer-by-Layer Assembly on DXM NPs 
20 mg/ml solutions of PDAC and PSS were prepared from their respective 
homopolymers and ultrapure water with ionic strengths of 0 or 0.5 M NaCl at pH 7.4. 
LbL NPs were constructed by the alternate adsorption of polyelectrolytes onto 
negatively charged DXM NPs until a desired layer number was obtained. Polyelectrolyte 
solutions were incubated with 10~20 mg/ml DXM NPs for 20 min followed by 
centrifugation and removal of supernatant. Three separate rinses with respective ionic 
strength were performed between each layer adsorption, Figure 3-1. 
 
 
 
 
  
 
 
 
 
Figure 3-1. The procedure of LbL coating on DXM NPs 
 
 
3.5 In Vitro DXM Release from LbL Assemblies 
Release studies of dexamethasone from PDAC/PSS LbL NPs were performed in 
vitro. 1.0 mL of NPs in PBS solution (pH 7.4) at a concentration of 0.2 mg/mL was 
placed in an eppendorf vial and gently shaken in a Thermo Scientific Precision 
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Reciprocal Water Bath 25 at 37 oC or at 60 oC. At various times, the NP solution was 
centrifuged at a speed of 10000 rpm for 20 min, and 500 μl supernatant was collected for 
further HPLC analysis. The pellet was resuspended in fresh 1.0 mL PBS to preserve sink 
condition. All the release experiments lasted 8 hours. All samples under the same 
condition were duplicated at least. Cumulative DXM release, as measured by HPLC, 
was quantified with release time.  
 
3.6 Characterization 
3.6.1 ζ -Potential measurements 
ζ –potential measurement is widely used for quantification of the electrical 
charge on colloids. It measures the potential difference between the charged surface of a 
dispersed particle and the medium. The absolute value of ζ –potential can be related the 
stability of colloids, where colloids with high ζ -potential are electrically stabilized while 
colloids with low ζ -potential tend to aggregate.59 Here, the surface charge of bare DXM 
NPs and each adsorbing layer was characterized by ζ -potential measured with a 
Brookhaven ZetaPALS instrument. Each sample was run twice with each run consisting 
of 10 data points. 
 
3.6.2 X-ray photoelectron spectroscopy 
X-ray photoelectron spectroscopy (XPS) is a surface chemistry analysis 
technique that measures elemental composition and the chemical state of elements 
within the surface of materials. A beam of X-rays irradiates the surface. The kinetic 
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energy and number of electrons that escape from material are obtained and presented in 
XPS spectra. Here, a Kratos Axis Ultra Imaging X-ray photoelectron spectrometer was 
used to determine the surface elemental composition of each layer. The X-ray source 
was monochromatic aluminum (1486.6 eV). A 10 μl sample solution was dropped onto a 
piece of aluminum foil and dried overnight. Survey spectra were collected from 0 to 
1200 eV with a pass energy of 160 eV.  
 
3.6.3 Field-emission scanning electron microscopy 
Images of bare DXM NPs were characterized by JEOL JSM-7500F field-
emission scanning electron microscopy (FE-SEM). 10 μl NP solutions were diluted with 
isopropanol, filtered using an 0.8 μl filter, and drop cast onto a TEM copper grid. 
Samples were dried under ambient conditions, and stored in a vacuum oven at room 
temperature for 1 day before imaging. 4 nm of palladium/platinum was sputtered on the 
sample to minimize charging. The acceleration voltage was set to 3.0 kV.  
 
3.6.4 Transmission electron microscopy 
Images of 4.5 and 8.5 bilayers of PDAC/PSS LbL-coated DXM NPs were 
characterized by a JEOL 1200 EX Transmission Electron Microscopy (TEM). Both LbL 
shells were assembled from 0.5 M NaCl. A 2 μl LbL NPs solution was dropped on 
copper grid and dried at the room temperature. A CCD camera (SIA 15 C) was used for 
digital images. All images were acquired at 100 kV accelerating voltage. 
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3.6.5 High performance liquid chromatography 
The concentration of DXM was assayed by high performance liquid 
chromatography (HPLC). HPLC uses high pressure to generate the flow that pass 
through a packed column. The components in a sample mixture being passed over the 
column are separated. Each component is identified and quantified using a detector. A 
reversed phase column was used in this study to separate components by polarity. A less 
polar molecule has more affinity to the filler material (silica) and thus elutes with a 
longer retention time. Each component appears as a peak in the chromatogram and its 
concentration can be quantified by integration of the area under each peak. 
Here, the DXM concentration was assayed using a Thermo Scientific Dionex 
Ultimate 3000 UHPLC equipped with an Acclaim 120 C18 Reversed-Phase LC Column 
(250×4.6 mm, 5 μm). The supernatant was mixed with acetonitrile (1:1 v/v) and filtered 
by 0.2 μm filter. DXM absorbance was measured by a Diode Array Detector at 242 nm 
with a retention time of 3.3 min in 1mL/min 70/30 acetronitrile/water mobile phase. 
Column temperature was set to 30 oC and the sample temperature was maintained at 20 
oC. Results were averaged from triplicate samples under the same condition. A 
calibration curve was obtained by plotting DXM integrated peak area versus DXM 
standard concentration.  
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4. RESULTS AND DISCUSSION 
 
 4.1 Introduction 
In this chapter, LbL nanoshells encapsulating DXM NPs were fabricated. The 
successful deposition of a PDAC/PSS LbL coating onto DXM NPs was confirmed by ζ -
potential, XPS, and TEM. The effect of varying (i) number of layers, (ii) ionic strength 
of the adsorption solutions, (iii) temperature, and (iv) outer-most layer on 
dexamethasone release in vitro is examined. Results indicate a thermo-responsive drug 
release from PDAC/PSS LbL nanoshells with tunable permeability by varying LbL 
assembly conditions.  
 
4.2 The Size and Morphology of DXM NPs 
Dexamethasone nanoparticles were fabricated by a two organic solvent 
evaporation technique described elsewhere.55 Briefly, a solution of hydrophobic drug in 
acetone was emulsified with a second organic solvent of n-Heptane. Solid DXM 
particles of an average size of 201  96 nm were formed (statistically obtained from 
different areas of SEM images). An FE-SEM image from a selected area is shown in 
Figure 4-1. The ζ -potential was -16 mV, which suggests that DXM NPs are negatively 
charged. The encapsulation efficiency determined by 3-1 was 35.3%. 
 
 
 
22 
 
          
 
 
 
 
  
 
 
Figure 4-1. FE-SEM of bare DXM NPs. 4 nm of palladium/platinum was 
sputtered on the sample to minimize charging. 
 
 
The modified solvent evaporation procedure described here relies on immiscible 
liquids to form droplets of drug which are hardened by solvent evaporation to form 
micro or nano particles.58 Under low heat, acetone evaporates first, leaving DXM NPs 
suspended in n-Heptane. High-speed stirring continued to ensure the complete removal 
of n-Heptane. This modified solvent evaporation technique provides an efficient way to 
fabricate NPs. However, problems appear with the large distribution of particle size. 
Further optimization on emulsification speed, surfactant type/concentration, and organic 
to water volume ratio may be performed to control the size distribution of particles.57 
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4.3 Layer-by-Layer Assembly on DXM NPs 
Layer-by-layer nanoshells were fabricated by assembling alternating layers of 
PDAC and PSS onto DXM NPs. Because each layer has its own characteristic elemental 
composition (PDAC has nitrogen and PSS has sulfur). X-ray photoelectron spectroscopy 
was used to analyze the surface composition of each deposited layer. From XPS survey 
scans in Figure 4-2, the binding energy at 168 eV representing for sulfur (S) 2p indicated 
deprotonated sulfonic acid. An increase in the S peak intensity corresponded to PSS 
layer adsorption and the intensity decreased after adding a layer of PDAC. The 
successful LbL coating on DXM NPs was also demonstrated by ζ -potential 
measurements, which characterize colloids surface charge and electrical stability (Figure 
4-3).60 A reversal in charge after each adsorbed layer and the high ζ –potential suggested 
that the polyelectrolytes were sequentially deposited.  
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Figure 4-2. XPS survey scans spectra with pass energy 160 eV of DXM NPs 
encapsulated increasing number of layers of PDAC/PSS assembled at 0.5 M NaCl. The 
sulfur 2p peak at 168 eV confirmed the presence of PSS. 
 
 
 
 
 
 
 
 
 
Figure 4-3. ζ –potential of two bilayers of PDAC/PSS LbL assemblies onto DXM NPs. 
The charge reversal after each layer deposited confirmed the successful LbL assembly 
on the DXM NP. 
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To visually examine the existence of the coating built on DXM NPs, TEM 
images of 4.5 and 8.5 bilayers of PDAC/PSS assembled at 0.5 M NaCl on DXM NPs are 
shown in Figure 4-4. The core appeared darker than the shell under TEM. This may be 
due to the difference in crystallinity of materials. DXM NPs are crystalline, while the 
layer is amorphous. At the magnification of 100,000, 4.5 bilayers were evident and the 
layer thickness was approximately 41.0 nm; 8.5 bilayers were evident and the layer 
thickness was approximately 72.1 nm.  
       
 
Figure 4-4. TEM of (left) (PDAC/PSS)4.5, (right) (PDAC/PSS)8.5 assembled at 0.5 M 
NaCl on DXM NPs at the magnification of 100,000. 
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4.4 In Vitro DXM Release from LbL Assemblies 
In our in vitro release study, the cumulative DXM release from PDAC/PSS LbL-
coated DXM NPs was investigated. The effect of varying (i) number of layers, (ii) ionic 
strength of the adsorption solutions, (iii) temperature, and (iv) outer-most layer on DXM 
release was examined.  
4.3.1 Influence of number of layers on DXM release 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-5. Cumulative DXM percentage release from a) Bare NPs (triangle) , 
(PDAC/PSS)4.5 LbL-coated DXM NPs assembled at 0.5 M NaCl (square), and 
(PDAC/PSS)8.5 LbL-coated DXM NPs assembled at 0.5M NaCl (circle), b) Bare NPs 
(triangle), (PDAC/PSS)4.5 LbL-coated DXM NPs assembled without NaCl (square), and 
(PDAC/PSS)8.5 LbL NPs assembled without NaCl (circle). Release experiments were 
carried out in PBS 7.4 at 37 oC. The Peppas model was applied to the release data from 
(PDAC/PSS)4.5 LbL NPs assembled without NaCl (red shot dash) and (PDAC/PSS)8.5 
LbL NPs assembled without NaCl (black short dash), as discussed later. 
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Figure 4-5 Continued. 
 
 
Figure 4-5 a and 4-5 b display the DXM cumulative percentage release at 37 oC 
from bare NPs, (PDAC/PSS)4.5 LbL-coated DXM NPs, and (PDAC/PSS)8.5 LbL-coated 
DXM NPs. It was observed that bare NPs exhibited a burst release of 70% in 2 hours, 
while after encapsulating these NPs into various number of PDAC/PSS layers, this burst 
effect was eliminated. In this experiment, DXM NPs were encapsulated into PDAC/PSS 
LbL shells and then subjected to PBS that allowed for their controlled release. The 
existence of PDAC/PSS LbL nanoshells could increase the bioavailability of DXM and 
maintain a sustained release.  
 It has been established that the permeability of LbL nanoshells is strongly 
dependent on the thickness of LbL, which is controlled by varying the number of layers 
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within a range of a few nanometers.61 From the results in Figure 4-5, for both ionic 
strengths explored, the release rate slowed down as number of layers increased. Within 8 
hours, 65.3  0.7% of DXM was released from (PDAC/PSS)4.5 LbL-coated DXM NPs 
assembled without NaCl, whereas 30  2% was released from (PDAC/PSS)8.5 LbL-
coated DXM NPs assembled without NaCl at 37 oC. For those LbL NPs assembled at 0.5 
M NaCl, 93.2 0.01% of DXM was released from (PDAC/PSS)4.5 LbL NPs, while 62.5
 0.08% was released from (PDAC/PSS)8.5 LbL-coated NPs. The trend suggests that the 
rate of DXM release from PDAC/PSS LbL nanoshells is a function of the thickness of 
shell. Similar trends were observed with paclitaxel NPs62 and furosemide microcrystals41 
encapsulated within LbL shells.  
With respect to film thickness, PDAC/PSS films assembled at 0.5 M NaCl grow 
exponentially, whereas PDAC/PSS films assembled without NaCl grow linearly. With 
equivalent number of layers, PDAC/PSS films assembled at 0.5 M NaCl are much 
thicker than films assembled without NaCl. However, the trends in Figure 4-6 have 
shown that the release rate was faster from exponentially growing LbL nanoshells. This 
is attributed to the “salt effect” and will be discussed in the subsequent section. 
The internal structure of the LbL nanoshell, such as the size and concentration of 
free volume cavities, is known to have a critical effect on the transport of small 
molecules through the shell. We postulate that the mechanism responsible for the 
difference in DXM release from LbL NPs assembled at different conditions may be 
associated with the properties of free volume cavities within the LbL nanoshell. As 
suggested by Quinn et al., for strong polyelectrolytes, the number of layers did not 
 
 
 
29 
 
change the free volume size but rather control the lateral gradient concentration, where 
there was more substrate compaction as the number of layers increased.44 Hence, the 
trend observed here is not due to the variation of free volume properties.  
The DXM release from PDAC/PSS LbL nanoshells with time appears to involve 
several stages that have been discussed before.63, 64 As bulk solution diffuses into shell, 
drug NPs dissolution starts. When the concentration of DXM inside the shell reaches its 
saturation solubility, the concentration gradient between the interior and the bulk 
remains time-independent. The rate of drug release is then controlled by the permeability 
of LbL nanoshells. After the core is completely dissolved, the concentration of DXM 
decreases until an equilibrium concentration is achieved, resulting in the maximum 
release. 
           
4.3.2 Influence of ionic strength on DXM release 
Figure 4-6 a and 4-6 b display the DXM cumulative percentage release at 37 oC 
from LbL-coated DXM NPs assembled at 0.5 M NaCl and LbL-coated DXM NPs 
assembled without NaCl. The release rate became faster as ionic strength increased. For 
8.5 bilayers LbL NPs, in 8 hours, 53  2% of DXM was released from those assembled 
at 0.5 M NaCl, while 30  2% was released from those assembled without NaCl. A 
similar trend was observed for 4.5 bilayers LbL-coated DXM NPs. Such behavior has 
been reported elsewhere40 and is associated with the free defects in polyelectrolyte 
complex.   
 
 
 
 
30 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-6. Cumulative DXM percentage release from a) (PDAC/PSS)4.5 LbL-coated 
DXM NPs assembled at 0.5 M NaCl (circle) and without NaCl (square), b) 
(PDAC/PSS)8.5 LbL-coated DXM NPs assembled at 0.5 M NaCl (circle) and without 
NaCl (square). Release experiments were carried out in PBS 7.4 at 37 oC. The Peppas 
model was applied to release data from (PDAC/PSS)8.5 LbL-coated DXM NPs 
assembled at  (red short dash) and without NaCl (black short dash). 
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The effect of ionic strength on the growth7 and various properties of LbL 
assemblies has been widely discussed.65, 66 At low ionic strength, LbL assemblies are 
elongated to form thin films, whereas at high ionic strength, they are in a coiled shape to 
form loops and tails. The difference in chain conformation is mainly due to a charge 
screening effect.67 It has been suggested that the high ionic strength during the build up 
process favors polymer chain interdiffusion, 68  leading to a fuzzy structure. Recent 
studies further demonstrated that for strong polyelectrolytes, an increase in assembly salt 
concentration yielded the same free volume size but increased the free volume 
concentration.44 Hence we postulate that the results observed in Figure 4-6 are likely 
attributed to the variation of free volume concentration, from many cavities at high ionic 
strength to a few cavities with similar size at low ionic strength.  
It is interesting to note that the addition of salt in the release buffer is also known 
to enhance the permeability of LbL assemblies.69 Added salt induces polyelectrolyte 
rearrangement and swells the LbL assembly, leading to polyelectrolyte binding site 
dissociation and new cavity formation.67 It has been suggested that by exposing LbL 
assemblies to buffers with variable salt concentrations, the permeability of LbL obeys a 
power law P~k[salt]n, where n is the ionic strength, k is proportionality constant and P is 
the permeability.70 Such a phenomenon is suggested to be associated with the free energy 
of interpolyelectrolyte interaction, i.e. increasing the ionic strength of the surrounding 
solution decreases the free energy of polyelectrolyte interactions, causing an increase in 
permeability.40 Changing the assembly and salt concentrations may induce nanopore 
formation. Caruso and co-workers introduced controlled nanometer-sized pores into 
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weak LbL assemblies by immersing them in pure water. Pores with 20-30 nm diameter 
size and 7-10 nm depth were formed in ten layers of PAH/PAA prepared from 0.2 M 
NaCl.71 However, a significant increase in the ionic strength of the surrounding solution 
may cause dramatic weakening of polyelectrolyte interactions, which leads to LbL 
destabilization and decomposition.37  
 
4.3.3 Influence of temperature on DXM release 
The dissolution profiles of DXM bare NPs in PBS (pH 7.4) at 37 oC and 60 oC 
were shown in Figure 4-7. The dissolution rate was enhanced at 60 oC, as 78 2% of 
DXM was released in 1 hour, as opposed to only 41 4% of DXM was dissolved at 37 
oC. This could be due to an increase in DXM solubility72 or diffusion coefficient upon 
heating. According to Noyes–Whitney equation73, an increase in saturation solubility or 
diffusion coefficient increases drug dissolution rate. 
 
 
 
 
 
 
a 
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Figure 4-7. Cumulative DXM release from bare NPs at 37 oC (square) and 60 oC 
(circle) in PBS 
 
 
To probe whether the glass transition at ~50 oC enhances the permeability of LbL 
nanoshells, the release of DXM from (PDAC/PSS)4.5 and (PDAC/PSS)8.5 LbL-coated 
DXM NPs assembled at 0.5 M NaCl at a temperature below and above the assemblies’ 
Tg was investigated, Figure 4-8 a and 4-8 c. As a control, the release from LbL NPs 
assembled without NaCl was carried out under the same conditions since no glass 
transition was observed in those assemblies, Figure 4-8 b and 4-8 d. Generally, the 
release rate became faster as temperature increased. However, the change in release rate 
with respect to temperature was more extreme for LbL-coated DXM NPs exhibiting no 
glass transition. Within 8 hours, the cumulative DXM release from (PDAC/PSS)8.5 LbL-
coated DXM NPs assembled without NaCl increased by ~40%, whereas it increased by 
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23% for (PDAC/PSS)4.5 LbL-coated DXM NPs assembled with 0.5 M NaCl. Although 
the absolute difference in the thermo-response of DXM release from LbL NPs varied 
from batch to batch, the overall trend was reproducible. 
 
 
 
 
 
 
 
 
 
Figure 4-8. Thermo-response of a) (PDAC/PSS)4.5 LbL-coated DXM NPs assembled at 
0.5 M NaCl, b) (PDAC/PSS)4.5 LbL-coated DXM NPs assembled without NaCl, c) 
(PDAC/PSS)8.5 LbL-coated DXM NPs assembled at  0.5 M NaCl, d) (PDAC/PSS)8.5 
LbL-coated DXM NPs assembled without NaCl. The Peppas model was applied to 
release data for (PDAC/PSS)8.5 LbL-coated DXM NPs at 60 
oC(red short dash) and 37 
oC (black short dash). 
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Figure 4-8 Continued 
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Figure 4-8 Continued 
 
 
The experimental data shown in Figure 4-8 disproves the hypothesis that an 
increase in PDAC/PSS LbL shells mobility or viscoelasticity enhances DXM thermo-
responsive release. It was expected that the DXM release from LbL NPs assembled at 
0.5 M NaCl would experience more dramatic response to temperature than those 
assembled without NaCl. However, the results did not support this assumption. In 
diffusion-controlled drug release, the diffusion of DXM occurs through water-filled 
cavities and is associated with a dynamic activation process. Considering Cohen and 
Turnbull free volume theory,74 the diffusing molecules, either DXM or water, resides 
temporally in a cavity and diffusion occurs when the solutes overcome a certain energy 
barrier and jump into the next cavity, or when two cavities meet each other and the 
solutes diffuse through one to another.75 The diffusion coefficient may be related to an 
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average jump distance, the thermal velocity of solute, and the probability that there is a 
cavity adjacent to solute. At a given temperature, the rate of diffusion is determined by 
the probability of finding a sufficient free volume cavity for solute to pass through.42 It 
was observed that a similar size but with a larger number of free volume cavity existed 
in strong layer pairs assembled at the higher salt concentration. This suggests a higher 
probability in PDAC/PSS LbL nanoshells having a free volume cavity when assembled 
at 0.5 M NaCl. As the temperature increases from 37 oC to 60 oC, there is a change in the 
film’s overall viscoelasticity of PDAC/PSS LbL assembled at 0.5 M NaCl14, allowing for 
polymer rearrangement and new cavity formation. However, there may be more change 
in probability of finding a free volume cavity of adequate size when using PDAC/PSS 
LbL assembled at 0.5 M NaCl, as compared to those assembled without NaCl, Figure 4-
9. 
 
 
 
 
 
 
 
 
Figure 4-9. Hypothetical schematic illustrations of PDAC/PSS LbL assemblies 
rearranging upon heating. 
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4.3.4 Odd-even effect 
Several groups have reported an “odd-even” effect for PDAC/PSS LbL 
capsules.34, 76 , 77  PSS-terminated capsules shrink upon heating, resulting in a denser 
sphere, whereas PDAC-terminated capsules swell. It was interesting for us to examine 
the DXM release from PSS-terminated LbL NPs at an elevated temperature. Figure 4-10 
shows the thermo-response of DXM release from (PDAC/PSS)4 LbL NPs assembled at  
0.5 M NaCl. More thermo-response was observed as compared to Figure 4-8 a, where 
PDAC was the outer-most layer. At both 37 oC and 60 oC, the release rate became 
slower from PSS-terminated LbL NPs, as compared to the release rate from PDAC-
terminated LbL NPs.  
In this present work, an “odd-even” effect was observed for core-shell 
PDAC/PSS-DXM NPs. As suggested by Vidyasagar et al.,14 upon heating, PSS-
terminated LbL films became more rigid and the hydrated mass decreased. Köhler and 
co-workers34,53, 78 also suggested that heating (PDAC/PSS)n microcapsules induced layers 
reorganization driven by two competing forces, i.e. the electrostatic forces and 
hydrophobic forces, which act outward and inward, respectively. Increasing temperature, 
for PSS-terminated capsules, tends to enhance hydrophobic interaction accompanied by 
a wall densification, whereas for PDAC-terminated capsules, such a tendency is 
overcompensated by the enhancement of electrostatic interactions resulting from the 
unbalanced ratio between polyelectrolytes. Köhler et al.45 reported a decrease in apparent 
mesh size from 13 to 5 nm for PSS-terminated capsules after incubation at 50 oC. These 
values are attributed to the defects within LbL films.  
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Figure 4-10. Cumulative DXM release from (PDAC/PSS)4 LbL-coated DXM NPs 
assembled at 0.5 M NaCl at 37 oC(square) and 60 oC(circle). 
 
 
4.3.5 Modeling of release kinetics 
Higuchi model 
To describe the DXM release rate from LbL NPs as the square root of time based 
on the principle of diffusion-controlled release, the Higuchi Model was applied,79 Figure 
4-11. The general form is:  
Mt/M∞=kH× t , with kH= ADCs2                       4-1 
Where Mt is the cumulative absolute drug release amount at time t, M∞ is the cumulative 
absolute drug release amount at infinite time, A is the drug mass per cubic centimeter in 
the matrix, D is the diffusional coefficient and Cs is the drug solubility.  
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Figure 4-11. Higuchi model fitting exploring a) layer effect, b) salt effect, c) thermo-
response of (PDAC/PSS)8.5 LbL-coated DXM NPs assembled at 0.5 M NaCl, d) thermo-
response of (PDAC/PSS)8.5 LbL-coated DXM NPs assembled without NaCl. The slope 
(k), axis intercept (a) and correlation coefficient (R2) were shown in Table 1. 
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Figure 4-11 Continued 
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Plots from Higuchi model show good linearity for all release profiles explored, 
indicating that diffusion is likely to be the main factor controlling DXM release from 
those delivery systems. Release rate constants are obtained from the slope and 
correlation coefficients, Table 4-1. The Higuchi constant kH is associated with the 
amount of drug per volume, diffusion coefficient, and drug solubility, and its value 
varied for different delivery systems. An increase in the number of layers appears to 
decrease the value of kH. An increase in the ionic strength appears to increase the value 
of kH. As temperature increased from 37 
oC to 60 oC, the kH of LbL-coated DXM NPs 
assembled at 0.5 M NaCl increased by 21%, whereas the kH of LbL-coated DXM NPs 
assembled without NaCl increased by 127%. 
 
 
Table 4-1. The Higuchi model fitting and release kinetics constants 
Sample 
Higuchi 
constant, kH
-1/2 A R
2 Figure reference 
(PDAC/PSS)4.5 
assembled without 
NaCl, 37 oC 
0.28 0.01 -0.08 0.03 0.99 Figure 4-11a 
(PDAC/PSS)8.5 
assembled without 
NaCl, 37 oC 
0.110 0.004 -0.013 0.007 0.99 
Figure 4-11a, 4-
11b, 4-11d 
(PDAC/PSS)8.5 
assembled at  0.5 M 
NaCl, 37 oC 
0.24 0.01 -0.04 0.01 0.99 Figure 4-11c 
(PDAC/PSS)8.5 
assembled without 
NaCl, 60 oC 
0.25 0.03 -0.01 0.07 0.93 Figure 4-11d 
(PDAC/PSS)8.5 
assembled at  0.5M 
NaCl, 60 oC 
0.29 0.03 0.11 0.03 0.98 Figure 4-11c 
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Korsmeyer–Peppas model (Power Law Equation) 
The Korsmeyer–Peppas model,80 or power law equation, Mt/M∞=kt
n, is a semi-
empirical relation describing the general solute release behavior of controlled release 
systems. (Mt)/(M∞) is the fractional drug release, t is the release time, k is a constant 
incorporating the coupling of solute diffusion and matrix relaxation phenomena, and n is 
the diffusional  exponent, indicating the release mechanism. For release from a swellable 
sphere, solute release kinetics are dependent on drug diffusion and polymer relaxation. If 
the polymer swelling front advances faster than the drug diffusion, Fickian diffusion 
kinetics are expected and is defined by n=0.43. If drug diffusion is much faster than the 
swelling front advances, zero-order kinetics is expected and is defined by n=0.85.81 In 
other words, higher n indicates that the release is more controlled by viscoelastic 
relaxation of the matrix, whereas lower n indicates that the release is more controlled by 
pure Fickian-diffusion. Many release behaviors fall between these limiting cases and is 
defined by n values between 0.43 and 0.85.82 Because it is valid for the first 60% of the 
normalized drug release, we were able to fit the release profiles with at least four points 
(including fixed zero) lying within 60% of fractional release, Figure 4-5b, 4-6b, 4-8c, 4-
8d, and 4-10. We obtained different values of exponent n and constant k as summarized 
in Table 4-2.  
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Table 4-2. The Korsmeyer–Peppas model fitting and possible mechanism of 
diffusional release from swellable controlled release systems 
 
Sample  
Diffusional 
exponent, n 
Kinetic 
constant, k/h-n 
R2 
Release 
mechanism 
Figure 
reference 
Spherical 
sample 
0.43 
-- -- 
Fickian 
diffusion 
-- 
0.43<n<0.85 
Anomalous(
non-Fickian) 
transport 
-- 
0.85 
Case-II 
transport 
-- 
(PDAC/PSS)4.5 
assembled 
without NaCl,  
37 oC 
0.580.05 0.220.02 0.99 
Non-Fickian 
diffusion 
Figure 4-5b 
(PDAC/PSS)8.5 
assembled 
without NaCl,  
37 oC 
0.530.02 0.0980.003 0.99 
Non-Fickian 
diffusion 
Figure 4-5b, 
4-6b, 4-8d 
(PDAC/PSS)8.5 
assembled at  
0.5 M NaCl,  
37 oC 
0.570.02 0.1940.005 0.99 
Non-Fickian 
diffusion 
Figure 4-6b, 
4-8c 
(PDAC/PSS)8.5 
assembled 
without NaCl,  
60 oC 
0.60.1 0.220.04 0.94 
Non-Fickian 
diffusion 
Figure 4-8d 
(PDAC/PSS)8.5 
assembled at 
0.5 M NaCl,  
60 oC 
0.390.03 0.4000.001 0.99 
Fickian 
diffusion 
Figure 4-8c 
(PDAC/PSS)4 
assembled at 
0.5 M NaCl,  
37 oC 
0.390.04 0.320.02 0.96 
Fickian 
diffusion 
Figure 4-10 
  
 
 
The Korsmeyer–Peppas model fits the experimental data well with over 95% 
goodness of fit, enabling a further understanding of possible release mechanisms. Except 
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for the DXM release at 60 oC from (PDAC/PSS)8.5 LbL nanoshells assembled at 0.5 M 
NaCl, the values of n are the same, lying between 0.43 and 0.85, indicating a non-
Fickian or anomalous transport mechanism.  For DXM release at 60 oC from 
(PDAC/PSS)8.5 LbL-coated DXM NPs assembled at 0.5 M NaCl, the value 0.390.03 of 
n indicates a Fickian transport mechanism. This result may not be reliable due to limited 
data points.   
We next examined the influence of various parameters on kinetic constant k in 
the power law. An increase in the number of layers appears to decrease the value of k. 
An increase in the ionic strength appears to increase the value of k. For both 
(PDAC/PSS)8.5 LbL NPs assembled at  0.5 M NaCl and without NaCl, k doubled as 
temperature increased. 
In the power law, k has a specific physical significance k=6(D/πa2)1/2 in the case 
of Fickian-diffusion, where D is the diffusional coefficient and a denotes the radius of a 
sphere.83 A decrease in k indicates either an increase in “a” or a decrease in D. As the 
number of layers increased, the films inner structure remained the same but thickness 
increased, suggesting an increase in “a”. However, the influence on D was hard to 
conclude. Because PDAC/PSS LbL shell assembled without NaCl is much thinner 
compared to those assembled at 0.5 M NaCl,14 as the ionic strength increased, “a” increased. 
The decrease in k should be associated with D. Upon heating, PDAC-terminated shells 
swell, resulting in an increase in “a”. Thus the increase in k as temperature increased was 
attributed to an increase in D. The difference of temperature response is hard to be 
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correlated with either diffusional coefficient or particles radius because the degree of 
particles swollen upon heating for the respective ionic strength has not been investigated.  
These new results allowed us to discuss the interplay of polymer chain mobility 
and free volume cavities affecting DXM release through PDAC/PSS LbL shells. Here, 
the rate of DXM release from exponentially growing LbL shells, which exhibits a glass 
transition, has more changes in polymer chain mobility. If polymer chains served to 
retard DXM movement through the assemblies, more changes in their mobility might 
cause more changes in the rate of DXM release. In contrast, the rate of DXM release 
from exponentially growing LbL shells saw less of a change upon heating, indicating 
that polymer chain mobility was not a dominant factor here. An increase in polymer 
chain mobility allows polymer rearrangement, which may lead to a change in the 
distribution of free volume cavities within the LbL. The difference of such a change in 
exponentially growing LbL shells and linearly growing LbL shells may explain the 
difference in the thermo-response of DXM release from these delivery systems. Thus it 
is interesting to next examine the properties of free volume cavities, including size and 
concentration, within exponentially growing LbL shells and linearly growing LbL shells 
at this present temperature window. A more clear explanation of how free volume 
cavities within LbL shells affect drug release will be discussed.   
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5. CONCLUSIONS 
 
A thermo-responsive NP-based drug delivery system was developed using 
PDAC/PSS as the model. The influence of various parameters on DXM release from 
PDAC/PSS LbL NPs, such as number of layers, ionic strength of the adsorption solution, 
temperature and outer-most layer, has been investigated. Results disprove the hypothesis 
that the glass transition of PDAC/PSS LbL nanoshells enhances drug release in this 
particular DXM NPs-PDAC/PSS system. 
DXM NPs at an average size of 201  96 nm were obtained by a modified 
solvent evaporation technique and then encapsulated into strong polyelectrolytes of 
PDAC/PSS using a LbL assembly technique. The successful layer adsorption was 
demonstrated by ζ –potential, XPS and TEM. By applying the power law to DXM 
release profiles obtained, DXM release from LbL NPs was estimated to be non-Fickian 
diffusion. Results have shown a controlled DXM release rate from NPs by tuning 
number of layers and ionic strength of the adsorption solution. Results have also 
indicated a more temperature response in the rate of DXM release from linearly growing 
LbL of PDAC/PSS (assembled without NaCl), which do not exhibit a glass transition, 
than from exponentially growing LbL of PDAC/PSS (assembled at 0.5 M NaCl), which 
exhibit a glass transition. Such a difference was attributed to the variation in the change 
of free volume cavities existing in LbL, suggesting a possible approach to enhance 
thermo-responsive DXM release from LbL nanoshells by tailoring the properties of 
cavities.  By tailoring the properties of cavities, an ideal thermo-responsive drug delivery 
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system may be obtained. This thermo-responsive NP-based drug delivery system with 
tunable permeability may possibly realize an “on” or “off” drug release mechanism in 
response to temperature, thus providing an alternative approach to delivering 
therapeutics with reduced toxic effects. 
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6. FUTURE WORK 
 
Future work will investigate the change in the properties of free volume cavities 
within exponentially growing PDAC/PSS LbL shells and linearly growing PDAC/PSS 
LbL shells upon heating, thus elucidating more straightforward causes behind these 
thermo-responsive drug release phenomena. Characterization tools such as PAS can be 
used to measure the properties of free volume cavities. Other LbL systems that exhibit 
glass transition behavior will also be investigated on the properties of free volume 
cavities and thermo-responsive drug release. Considering factors affecting internal 
structure of LbL films, such as free volume cavities and polymer chain mobility, an ideal 
thermo-responsive drug delivery system may be obtained. Furthermore, in vitro release 
studies for investigated thermo-responsive delivery systems will be explored when 
exposed to an “on” or “off” drug release mechanism in response to heat.  
The long term goal in this research is to develop a remotely triggered light-
responsive drug delivery system. Near-infrared light (NIR) (650-900 nm) has become an 
attractive light resource because it is less harmful and allows for penetration of deep 
tissues. By inserting gold NPs into capsules wall, NIR-induced heat generation on gold 
NPs will raise the capsules’ temperature, which may lead to an enhancement in drug 
permeability; therefore, remotely triggered NIR-responsive drug release can be achieved. 
Overall, the present research offers an opportunity in the development of the further 
combination of hyperthermia therapy with chemotherapy and photothermal therapy in 
cancer treatment. 
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